Endobronchial Coil System versus Standard-of-Care Medical Management in the Treatment of Subjects with Severe Emphysema.
Bronchoscopic lung volume reduction
Emphysema
Endobronchial coil treatment
Hyperinflation
Journal
Respiration; international review of thoracic diseases
ISSN: 1423-0356
Titre abrégé: Respiration
Pays: Switzerland
ID NLM: 0137356
Informations de publication
Date de publication:
Historique:
received:
13
01
2021
accepted:
04
03
2021
pubmed:
10
5
2021
medline:
16
12
2021
entrez:
9
5
2021
Statut:
ppublish
Résumé
Bronchoscopic lung volume reduction using endobronchial coils is a new treatment for patients with severe emphysema. To date, the benefits have been modest and have been suggested to be much larger in patients with severe hyperinflation and nonmulti-comorbidity. We aimed to evaluate the efficacy and safety of endobronchial coil treatment in a randomized multicenter clinical trial using optimized patient selection. Patients with severe emphysema on HRCT scan with severe hyperinflation (residual volume [RV] ≥200% predicted and RV/total lung capacity [TLC] >55%) were randomized to coil treatment or control. Primary outcome measures were differences in the forced expiratory volume in 1 s (FEV1) and St George's Respiratory Questionnaire (SGRQ) total score at 6 months. Due to premature study termination, a total of 120 patients (age 63 ± 7 years, FEV1 29 ± 7% predicted, RV 251 ± 41% predicted, RV/TLC 67 ± 6%, and SGRQ 58 ± 13 points), instead of 210 patients, were randomized. At study termination, 91 patients (57 coil and 34 control) had 6-month results available. Analyses showed significantly greater improvements in favor of the coil group. The increase in FEV1 was greater in the coil group than that in the control group by + 10.3 [+4.7 to +16.0] % and in SGRQ by -10.6 [-15.9 to -5.4] points. At study termination, there were 5 (6.8%) deaths in the coil cohort reported. Despite early study termination, coil treatment compared to control results in a significant improvement in the lung function and quality of life benefits for up to 6 months in patients with emphysema and severe hyperinflation. These improvements were of clinical importance but were associated with a higher likelihood of serious adverse events.
Sections du résumé
BACKGROUND
BACKGROUND
Bronchoscopic lung volume reduction using endobronchial coils is a new treatment for patients with severe emphysema. To date, the benefits have been modest and have been suggested to be much larger in patients with severe hyperinflation and nonmulti-comorbidity.
OBJECTIVE
OBJECTIVE
We aimed to evaluate the efficacy and safety of endobronchial coil treatment in a randomized multicenter clinical trial using optimized patient selection.
METHOD
METHODS
Patients with severe emphysema on HRCT scan with severe hyperinflation (residual volume [RV] ≥200% predicted and RV/total lung capacity [TLC] >55%) were randomized to coil treatment or control. Primary outcome measures were differences in the forced expiratory volume in 1 s (FEV1) and St George's Respiratory Questionnaire (SGRQ) total score at 6 months.
RESULTS
RESULTS
Due to premature study termination, a total of 120 patients (age 63 ± 7 years, FEV1 29 ± 7% predicted, RV 251 ± 41% predicted, RV/TLC 67 ± 6%, and SGRQ 58 ± 13 points), instead of 210 patients, were randomized. At study termination, 91 patients (57 coil and 34 control) had 6-month results available. Analyses showed significantly greater improvements in favor of the coil group. The increase in FEV1 was greater in the coil group than that in the control group by + 10.3 [+4.7 to +16.0] % and in SGRQ by -10.6 [-15.9 to -5.4] points. At study termination, there were 5 (6.8%) deaths in the coil cohort reported.
CONCLUSION
CONCLUSIONS
Despite early study termination, coil treatment compared to control results in a significant improvement in the lung function and quality of life benefits for up to 6 months in patients with emphysema and severe hyperinflation. These improvements were of clinical importance but were associated with a higher likelihood of serious adverse events.
Identifiants
pubmed: 33965944
pii: 000515744
doi: 10.1159/000515744
pmc: PMC8491498
doi:
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
804-810Informations de copyright
© 2021 The Author(s) Published by S. Karger AG, Basel.
Références
COPD. 2005 Mar;2(1):111-24
pubmed: 17136971
Respiration. 2019;97(6):548-557
pubmed: 30836374
Respiration. 2014;88(2):116-25
pubmed: 24902999
Respirology. 2020 Nov;25(11):1160-1166
pubmed: 32267059
Chest. 2019 May;155(5):928-937
pubmed: 30797746
Eur Respir J. 2012 Nov;40(5):1137-41
pubmed: 22441742
JAMA. 2016 May 24-31;315(20):2178-89
pubmed: 27179849
Respiration. 2019;98(6):512-520
pubmed: 31743933
Eur Respir J. 2015 Dec;46(6):1598-604
pubmed: 26493797
Respiration. 2015;90(2):136-45
pubmed: 26112380
Lancet Respir Med. 2013 May;1(3):233-40
pubmed: 24429129
JAMA. 2016 Jan 12;315(2):175-84
pubmed: 26757466
Int J Chron Obstruct Pulmon Dis. 2020 Apr 23;15:871-881
pubmed: 32368033
Respiration. 2019;97(1):34-41
pubmed: 30121662